Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4898)	11/7/2001 4:13:20 PM
From: aknahow	Respond to of 52153

Peter, that's, my point. I quoted the $1 billion number I had heard them also say $2 billion, at another conference. When they themselves say $500 million, there is no comment from anyone, except yours which is to restate what they first said. Does no one care what BGEN says? ""PSORIASIS DRUG SEEN LAUNCHING BY Q1 2003 Biogen said it expects its psoriasis drug Amevive to be launched by the end of 2002 or the first quarter of 2003, confirming fears of some analysts that the expected 2002 launch might be delayed into 2003. Company officials predicted the psoriasis drug, if approved, could achieve annual sales of $500 million within three years.""

To: Biomaven who wrote (4898)	11/7/2001 4:21:01 PM
From: Icebrg	Read Replies (2) \| Respond to of 52153

Re.: Psoriasis market. Adams, Harkness & Hill put out a 40+ page psoriasis report in August. For those finding their way around their site the report can be picked up under the "search name" Abgenix. Most probably under other names too as long as AHH are covering the companies in question. Anyhow, these are AHHs estimate of the market for psoriasis drugs year 2006. They have calculated with a yearly drug cost of USD 7.500, which however they admit might be too low for some of the companies. Turnover is in mUSD. Drug...........US...........Europe.......Total Xanelim........675..........325.........1.000 Amevive........270..........122...........392 Remicade.......145...........35...........180 Enbrel.........655............-...........655 (ps. arthritis) Zenepax........207...........38...........245 ABX-IL8.........63...........12............75 IDEC-114.........-............-.............- MEDI-507.......275............-...........275 They seem to believe that Amevive will start losing sales to the relative newcomers like Zenepax and MEDI-507 in 2006 compared to 2005, while for example sales of Xanelim continues to increase. Ice